Clinical Trial Update: Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial of PF-06473871 to reduce hypertrophic scars after recurrent post-revision surgery completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Scar

Drugs mentioned

• PF-06473871 (PF-06473871)

Snippet

Sponsor: Pfizer | Conditions: Reduction of Hypertrophic Skin Scarring | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20